Clinicopathological and Prognostic Values of Fibronectin and Integrin αvβ3 Expression in Primary Osteosarcoma

Overview

Journal World J Surg Oncol

Publisher Biomed Central

Specialties General Surgery
Oncology

Date 2019 Jan 30

PMID 30691475

Citations 21

Authors

Kai Shi

Sheng-Lin Wang

Bin Shen

Feng-Qiang Yu

Dan-Feng Weng

Jian-Hua Lin

Affiliations

Soon will be listed here.

Abstract

Background: Osteosarcoma is a malignant bone tumor with a high potential for lung metastasis, and the prognosis for patients with metastatic disease is very poor. The interaction between fibronectin (FN) and integrin αvβ3 in soft-tissue sarcoma promotes cell migration, invasion, and lung metastasis. This study aimed to investigate the prognostic significance of FN and αvβ3 in osteosarcoma.

Methods: Immunohistochemistry and western blotting were used to detect the expression of FN and αvβ3 in 60 osteosarcoma specimens and in 30 osteochondroma specimens. Furthermore, correlations of FN and αvβ3 with the clinicopathological features of osteosarcoma patients were analyzed using the χ test and Fisher's exact test. Disease-free survival and overall survival of osteosarcoma patients were assessed using the Kaplan-Meier method and Cox proportional hazards model. The predictive accuracy of the model was determined by the Harrell concordance index.

Results: FN (P < 0.05) and αvβ3 (P < 0.05) were overexpressed in osteosarcoma specimens compared with osteochondroma specimens. High FN expression was associated with a poor response to chemotherapy (P = 0.001) and poor disease-free (P < 0.001) and overall (P < 0.001) survival. High expression of αvβ3 was linked to an advanced surgical stage (P = 0.028), a poor response to chemotherapy (P = 0.002), and both poor disease-free survival (P < 0.001) and overall survival (P < 0.001). FN and αvβ3 co-expression were associated with sex (P = 0.011), an advanced surgical stage (P = 0.013), and a poor response to chemotherapy (P = 0.002). Moreover, high expression of both proteins can serve as an independent prognostic value for reduced survival time in osteosarcoma patients.

Conclusions: The results of this study suggest that FN and αvβ3 expression is associated with an unfavorable clinical outcome of osteosarcoma, and these molecules may constitute attractive therapeutic targets for osteosarcoma treatment. To improve the survival of osteosarcoma patients, further investigations are required to clarify their prognostic values in a larger population.

Citing Articles

Interaction of integrin αβ and fibronectin under fluid shear forces: implications for tumor cell adhesion and migration.

Zhuo P, Li Q, Yang B, Li N, Luo Z, Zhang F Front Cell Dev Biol. 2025; 13:1512672.

PMID: 40070879 PMC: 11894259. DOI: 10.3389/fcell.2025.1512672.

Osteosarcoma tumor microenvironment: the key for the successful development of biologically relevant 3D in vitro models.

Rodrigues J, Sarmento B, Leite Pereira C In Vitro Model. 2025; 1(1):5-27.

PMID: 39872973 PMC: 11756501. DOI: 10.1007/s44164-022-00008-x.

RNF135 Promotes Human Osteosarcoma Cell Growth and Inhibits Apoptosis by Upregulating the PI3K/AKT Pathway.

Chen B, Zhang Y, Song G, Wei X Cancer Rep (Hoboken). 2024; 7(8):e2159.

PMID: 39118262 PMC: 11310095. DOI: 10.1002/cnr2.2159.

Pediatric Solid Cancers: Dissecting the Tumor Microenvironment to Improve the Results of Clinical Immunotherapy.

Belgiovine C, Mebelli K, Raffaele A, De Cicco M, Rotella J, Pedrazzoli P Int J Mol Sci. 2024; 25(6).

PMID: 38542199 PMC: 10970338. DOI: 10.3390/ijms25063225.

Prospects and Advances in Adoptive Natural Killer Cell Therapy for Unmet Therapeutic Needs in Pediatric Bone Sarcomas.

Bareke H, Ibanez-Navarro A, Guerra-Garcia P, Gonzalez Perez C, Rubio-Aparicio P, Plaza Lopez de Sabando D Int J Mol Sci. 2023; 24(9).

PMID: 37176035 PMC: 10178897. DOI: 10.3390/ijms24098324.

References

Koistinen P, Pulli T, Uitto V, Nissinen L, Hyypia T, Heino J . Depletion of alphaV integrins from osteosarcoma cells by intracellular antibody expression induces bone differentiation marker genes and suppresses gelatinase (MMP-2) synthesis. Matrix Biol. 1999; 18(3):239-51. DOI: 10.1016/s0945-053x(99)00022-0. View

Lessey B, Damjanovich L, Coutifaris C, Castelbaum A, Albelda S, Buck C . Integrin adhesion molecules in the human endometrium. Correlation with the normal and abnormal menstrual cycle. J Clin Invest. 1992; 90(1):188-95. PMC: 443080. DOI: 10.1172/JCI115835. View

Kilpadi K, Sawyer A, Prince C, Chang P, Bellis S . Primary human marrow stromal cells and Saos-2 osteosarcoma cells use different mechanisms to adhere to hydroxylapatite. J Biomed Mater Res A. 2004; 68(2):273-85. DOI: 10.1002/jbm.a.20043. View

Kilian O, Dahse R, Alt V, Zardi L, Rosenhahn J, Exner U . Expression of EDA+ and EDB+ fibronectin splice variants in bone. Bone. 2004; 35(6):1334-45. DOI: 10.1016/j.bone.2004.08.008. View

Duan X, Jia S, Zhou Z, Langley R, Bolontrade M, Kleinerman E . Association of alphavbeta3 integrin expression with the metastatic potential and migratory and chemotactic ability of human osteosarcoma cells. Clin Exp Metastasis. 2005; 21(8):747-53. DOI: 10.1007/s10585-005-0599-6. View

Yang R, Chiang H, Tang C, Yeh C, Huang T . Rhodostomin inhibits thrombin-enhanced adhesion of ROS 17/2.8 cells through the blockade of alphavbeta3 integrin. Toxicon. 2005; 46(4):387-93. DOI: 10.1016/j.toxicon.2005.05.002. View

Zhang J, Zhi H, Zhou C, Ding F, Luo A, Zhang X . Up-regulation of fibronectin in oesophageal squamous cell carcinoma is associated with activation of the Erk pathway. J Pathol. 2005; 207(4):402-9. DOI: 10.1002/path.1846. View

Gramoun A, Shorey S, Bashutski J, Dixon S, Sims S, Heersche J . Effects of Vitaxin, a novel therapeutic in trial for metastatic bone tumors, on osteoclast functions in vitro. J Cell Biochem. 2007; 102(2):341-52. DOI: 10.1002/jcb.21296. View

Ta H, Dass C, Choong P, Dunstan D . Osteosarcoma treatment: state of the art. Cancer Metastasis Rev. 2009; 28(1-2):247-63. DOI: 10.1007/s10555-009-9186-7. View

10.

Desgrosellier J, Cheresh D . Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2009; 10(1):9-22. PMC: 4383089. DOI: 10.1038/nrc2748. View

11.

Huttenlocher A, Horwitz A . Integrins in cell migration. Cold Spring Harb Perspect Biol. 2011; 3(9):a005074. PMC: 3181029. DOI: 10.1101/cshperspect.a005074. View

12.

Na K, Bacchini P, Bertoni F, Kim Y, Park Y . Syndecan-4 and fibronectin in osteosarcoma. Pathology. 2012; 44(4):325-30. DOI: 10.1097/PAT.0b013e328353447b. View

13.

Zhang Y, Li L, Zhu J, Kuang H, Dong S, Wang H . In vitro observations of self-assembled ECM-mimetic bioceramic nanoreservoir delivering rFN/CDH to modulate osteogenesis. Biomaterials. 2012; 33(30):7468-77. DOI: 10.1016/j.biomaterials.2012.06.095. View

14.

Liang C, Chiu S, Hsu I, Wu Y, Tsai Y, Ke J . α-Catulin drives metastasis by activating ILK and driving an αvβ3 integrin signaling axis. Cancer Res. 2012; 73(1):428-38. DOI: 10.1158/0008-5472.CAN-12-2095. View

15.

Rhee S, Han I, Lee M, Cho H, Oh J, Kim H . Role of integrin-linked kinase in osteosarcoma progression. J Orthop Res. 2013; 31(10):1668-75. DOI: 10.1002/jor.22409. View

16.

Ma L, Lee S, Lin L, Chen T, Chang I, Hsu H . Fibronectin overexpression is associated with latent membrane protein 1 expression and has independent prognostic value for nasopharyngeal carcinoma. Tumour Biol. 2013; 35(2):1703-12. DOI: 10.1007/s13277-013-1235-8. View

17.

Mortara L, Orecchia P, Castellani P, Borsi L, Carnemolla B, Balza E . Schedule-dependent therapeutic efficacy of L19mTNF-α and melphalan combined with gemcitabine. Cancer Med. 2013; 2(4):478-87. PMC: 3799282. DOI: 10.1002/cam4.89. View

18.

Dutour A, Josserand V, Jury D, Guillermet S, Decouvelaere A, Chotel F . Targeted imaging of α(v)β(3) expressing sarcoma tumor cells in vivo in pre-operative setting using near infrared: a potential tool to reduce incomplete surgical resection. Bone. 2014; 62:71-8. DOI: 10.1016/j.bone.2014.02.004. View

19.

Kansara M, Teng M, Smyth M, Thomas D . Translational biology of osteosarcoma. Nat Rev Cancer. 2014; 14(11):722-35. DOI: 10.1038/nrc3838. View

20.

Stucci S, Tucci M, Passarelli A, Silvestris F . Avβ3 integrin: Pathogenetic role in osteotropic tumors. Crit Rev Oncol Hematol. 2015; 96(1):183-93. DOI: 10.1016/j.critrevonc.2015.05.018. View